Glucotrack (GCTK) Capital Expenditures (2010 - 2025)

Glucotrack (GCTK) posted Capital Expenditures of $20000.0 for Q4 2025, down 70.15% on a QoQ basis from $67000.0 in Q3 2025.

Glucotrack (GCTK) Capital Expenditures (2010 - 2025) Analysis & Trends

Glucotrack's Capital Expenditures history runs 15 years deep, the most recent figure standing at $20000.0 for Q4 2025.

Quarterly Capital Expenditures changed N/A year-over-year to $20000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $96000.0 (down 7.69% YoY) and the FY2025 annual result came in at $96000.0, down 7.69% from the prior year.
Capital Expenditures was $20000.0 for Q4 2025 at Glucotrack, down from $67000.0 in the prior quarter.
Across five years, Capital Expenditures topped out at $67000.0 in Q3 2025 and bottomed at -$3000.0 in Q4 2022.
A 4-year average of $25125.0 and a median of $16000.0 in 2024 frame the typical range for Capital Expenditures.
Annual changes were most pronounced in 2022 — Capital Expenditures tumbled 175.0% — and 2025, when it jumped 103.03%.
Glucotrack's Capital Expenditures stood at $4000.0 in 2021, then tumbled by 175.0% to -$3000.0 in 2022, then surged by 1200.0% to $33000.0 in 2024, then plunged by 39.39% to $20000.0 in 2025.
Business Quant data shows GCTK's Capital Expenditures at $20000.0 in Q4 2025, $67000.0 in Q3 2025, and $9000.0 in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capital Expenditures (Qtr)
1	Alcon	32,734,969.19 Bn	32,734,967.53 Bn	1.53 Bn	-139.00 Mn
2	Intuitive Surgical	117.50 Bn	112.41 Bn	1.96 Bn	-34.50 Mn
3	Becton Dickinson	42.93 Bn	42.11 Bn	2.15 Bn	125.00 Mn
4	Medline	30.82 Bn	36.66 Bn	1.84 Bn	96.00 Mn
5	Resmed	27.90 Bn	26.23 Bn	890.98 Mn	33.65 Mn
6	West Pharmaceutical Services	26.76 Bn	26.23 Bn	329.20 Mn	43.20 Mn
7	Cooper Companies	15.30 Bn	15.16 Bn	735.40 Mn	86.40 Mn
8	Solventum	13.46 Bn	12.90 Bn	1.10 Bn	84.00 Mn
9	Align Technology	12.02 Bn	10.96 Bn	736.59 Mn	30.79 Mn
10	Glucotrack	33.48	-7.38 Mn	-	20,000.00

Download Data